Product Overview

The investigational products are at various stages of development for the potential treatment of various disorders as listed below.

Titan is focused on the late-stage development and commercialization of innovative treatments for central nervous system (CNS) disorders. Our three late-stage programs currently include potential treatments for schizophrenia, opioid addiction, chronic pain and Parkinson’s disease.

2008 Milestones

  • Iloperidone For the potential treatment of schizophrenia
    NDA filed with FDA with action date in July, 2008
  • Probuphine® For the potential treatment of opioid addiction
    First controlled Phase III results for the potential treatment of opioid addiction expected in the third quarter of 2008
  • Probuphine® For the potential treatment of chronic pain
    Start of Phase II trial for chronic pain expected in 2008

Titan minimizes development risk by focusing on programs with previously established proof-of-concept. This approach has yielded a robust pipeline of product candidates that have the potential to address substantial markets with significant unmet medical needs.

Disclaimer for Chart
Information about Titan’s R&D pipeline is updated on a quarterly basis, based on publicly available information. Although we make a good faith effort to keep this content as current as possible, we do not have a duty to update information posted on our web site, and we will not be liable for any failure to update such information.